Characteristics of patient, grafts, and GVHD prophylaxis
| Case no. . | Age, y . | Previous treatment . | Interval from diagnosis to UCBT, mo . | Previous transfusion times (RBCs/platelet) . | Disease status at UCBT . | HLA match . | HLA Ab (reactive to CB) . | ABO group (R/D) . | TNC × 107/kg . | CD34+, × 105/kg . | GVHD prophylaxis . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | CSA | 3 | 11/14 | SAA | 4/6 | NT | A/A | 4.00 | 1.23 | CSA |
| 2 | 20 | ATG + CSA | 78 | > 20/> 20 | VSAA | 4/6 | NT | B/O | 2.65 | 1.07 | CSA |
| 3 | 22 | ATG + CSA, PSL | 157 | > 20/> 20 | SAA | 4/6 | NT | A/O | 2.26 | 0.27 | Tac |
| 4 | 26 | ATG + CSA | 3 | > 20/> 20 | VSAA | 5/6 | NT | A/A | 2.65 | 0.70 | Tac |
| 5 | 59 | ATG + CSA | 8 | > 20/> 20 | SAA | 5/6 | Positive (no) | O/O | 2.15 | 1.52 | Tac + MMF |
| 6 | 49 | ATG + CSA, PSL | 12 | > 20/> 20 | VSAA | 3/6 | NT | A/A | 2.04 | 0.62 | Tac + MMF |
| 7 | 70 | None | 1 | 5/8 | Fulminant | 4/6 | Positive (yes) | A/O | 4.39 | 1.29 | Tac + MMF |
| 8 | 52 | None | 1 | 4/6 | Fulminant | 4/6 | NT | AB/A | 3.20 | 0.49 | Tac + MMF |
| 9 | 46 | ATG + CSA | 45 | > 20/> 20 | VSAA | 4/6 | Positive (no) | AB/O | 1.83 | 0.42 | Tac + MMF |
| 10 | 49 | ATG + CSA, PSL | 327 | > 20/> 20 | VSAA | 6/6 | Positive (no) | B/O | 2.34 | 0.82 | Tac + MMF |
| 11 | 65 | CSA | 6 | 16/> 20 | VSAA | 6/6 | Positive (no) | A/A | 3.31 | 0.56 | Tac + MMF |
| 12 | 31 | ATG + CSA, PSL | 215 | > 20/> 20 | SAA | 4/6 | Positive (no) | B/O | 2.09 | 1.26 | Tac + MMF |
| Case no. . | Age, y . | Previous treatment . | Interval from diagnosis to UCBT, mo . | Previous transfusion times (RBCs/platelet) . | Disease status at UCBT . | HLA match . | HLA Ab (reactive to CB) . | ABO group (R/D) . | TNC × 107/kg . | CD34+, × 105/kg . | GVHD prophylaxis . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | CSA | 3 | 11/14 | SAA | 4/6 | NT | A/A | 4.00 | 1.23 | CSA |
| 2 | 20 | ATG + CSA | 78 | > 20/> 20 | VSAA | 4/6 | NT | B/O | 2.65 | 1.07 | CSA |
| 3 | 22 | ATG + CSA, PSL | 157 | > 20/> 20 | SAA | 4/6 | NT | A/O | 2.26 | 0.27 | Tac |
| 4 | 26 | ATG + CSA | 3 | > 20/> 20 | VSAA | 5/6 | NT | A/A | 2.65 | 0.70 | Tac |
| 5 | 59 | ATG + CSA | 8 | > 20/> 20 | SAA | 5/6 | Positive (no) | O/O | 2.15 | 1.52 | Tac + MMF |
| 6 | 49 | ATG + CSA, PSL | 12 | > 20/> 20 | VSAA | 3/6 | NT | A/A | 2.04 | 0.62 | Tac + MMF |
| 7 | 70 | None | 1 | 5/8 | Fulminant | 4/6 | Positive (yes) | A/O | 4.39 | 1.29 | Tac + MMF |
| 8 | 52 | None | 1 | 4/6 | Fulminant | 4/6 | NT | AB/A | 3.20 | 0.49 | Tac + MMF |
| 9 | 46 | ATG + CSA | 45 | > 20/> 20 | VSAA | 4/6 | Positive (no) | AB/O | 1.83 | 0.42 | Tac + MMF |
| 10 | 49 | ATG + CSA, PSL | 327 | > 20/> 20 | VSAA | 6/6 | Positive (no) | B/O | 2.34 | 0.82 | Tac + MMF |
| 11 | 65 | CSA | 6 | 16/> 20 | VSAA | 6/6 | Positive (no) | A/A | 3.31 | 0.56 | Tac + MMF |
| 12 | 31 | ATG + CSA, PSL | 215 | > 20/> 20 | SAA | 4/6 | Positive (no) | B/O | 2.09 | 1.26 | Tac + MMF |
RBC indicates red blood cell; CB, cord blood; R, recipient; D, donor; TNC, total nucleated cells; CSA, cyclosporine-A; ATG, antithymocyte globulin; PSL, prednisone; VSAA, very severe aplastic anemia; NT, not tested; Tac, tacrolimus; and MMF, mycophenolate mofetil.